Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | Director | May 29, 2026 | June 01, 2026 |
| Evelo Biosciences, Inc.EVLO · Entity 108468 | CFO | January 28, 2020 | January 30, 2020 |
| GENOCEA BIOSCIENCES, INC.GNCA · Entity 12635 | Chief Financial Officer | February 08, 2018 | February 12, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date May 29, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,010 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Exercise / conversion · Acquired 2,010 · Balance 2,010 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Exercise / conversion · Disposed 2,010 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,311 |
Reported balance
After 2026-05-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-29 · Grant · Acquired 9,311 · Balance 9,311 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended. |
| Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.66 · Expires 2036-05-28 | Direct | 16,004 |
Reported balance
After 2026-05-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-29 · Grant · Acquired 16,004 · Balance 16,004 F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F2: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.
F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended.
Evelo Biosciences, Inc.
Report date January 28, 2020 · Filed January 30, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.06 · Expires 2030-01-27 | Direct | 106,000 |
Reported balance
After 2020-01-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-28 · Grant · Acquired 106,000 · Balance 106,000 F1: These options will vest in forty-eight (48) substantially equal installments at the end of each monthly anniversary of January 9, 2020, subject to continued employment on such dates. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.06 · Expires 2030-01-27 | Direct | 48,000 |
Reported balance
After 2020-01-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-28 · Grant · Acquired 48,000 · Balance 48,000 F2: These options will vest as to 50% of the total grant on January 9, 2022 and as to the remaining 50% on January 9, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: These options will vest in forty-eight (48) substantially equal installments at the end of each monthly anniversary of January 9, 2020, subject to continued employment on such dates.
F2: These options will vest as to 50% of the total grant on January 9, 2022 and as to the remaining 50% on January 9, 2023.
GENOCEA BIOSCIENCES, INC.
Report date February 08, 2018 · Filed February 12, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.98 · Expires 2028-02-07 | Direct | 217,708 |
Reported balance
After 2018-02-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-08 · Grant · Acquired 217,708 · Balance 217,708 F1: The options granted will vest annually in 48 equal monthly installments beginning on the first monthly anniversary of the grant date. The Company's Board of Directors also approved on February 8, 2018 that, subject to stockholder approval, Jonathan Poole will receive 257,292 additional options with the same grant date, at the same exercise price and pursuant to the same vesting schedule. |
Filing footnotes · ownership attribution and instrument terms
F1: The options granted will vest annually in 48 equal monthly installments beginning on the first monthly anniversary of the grant date. The Company's Board of Directors also approved on February 8, 2018 that, subject to stockholder approval, Jonathan Poole will receive 257,292 additional options with the same grant date, at the same exercise price and pursuant to the same vesting schedule.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2026 Filed Jun 1, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 9,311 | $0.00 | $0.00 |
DisclosureSEC source: 0001604689-26-000009 · form4-06012026_060606.xml · derivative · entry 4 Poole Jonathan · CIK 0001604689 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,311 Underlying: Common Stock · 9,311 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended. F4 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 16,004 | $0.00 Strike: $21.66 | $0.00 |
DisclosureSEC source: 0001604689-26-000009 · form4-06012026_060606.xml · derivative · entry 3 Poole Jonathan · CIK 0001604689 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,004 Underlying: Common Stock · 16,004 shares Expires 2036-05-28 F3 · derivative.exercise_date: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 2,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001604689-26-000009 · form4-06012026_060606.xml · derivative · entry 2 Poole Jonathan · CIK 0001604689 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. F2 · derivative.expiration_date: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 2,010 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001604689-26-000009 · form4-06012026_060606.xml · nonDerivative · entry 1 Poole Jonathan · CIK 0001604689 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| March 03, 2026 Filed Mar 20, 2026 22:01 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 2,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001604689-26-000006 · form4-03202026_100313.xml · derivative · entry 4 Poole Jonathan · CIK 0001604689 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,010 Underlying: Common Stock · 2,010 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F5 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. F5 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| March 03, 2026 Filed Mar 20, 2026 22:01 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 4,218 | $0.00 | $0.00 |
DisclosureSEC source: 0001604689-26-000006 · form4-03202026_100313.xml · derivative · entry 3 Poole Jonathan · CIK 0001604689 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,218 Underlying: Common Stock · 4,218 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest in equal annual installments over three years following the date of grant such that the restricted stock units will be fully vested on the third anniversary of the date of grant. F4 · derivative.expiration_date: The restricted stock units will vest in equal annual installments over three years following the date of grant such that the restricted stock units will be fully vested on the third anniversary of the date of grant. Read SEC document |
| March 03, 2026 Filed Mar 20, 2026 22:01 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 3,565 | $0.00 Strike: $22.50 | $0.00 |
DisclosureSEC source: 0001604689-26-000006 · form4-03202026_100313.xml · derivative · entry 2 Poole Jonathan · CIK 0001604689 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,565 Underlying: Common Stock · 3,565 shares Expires 2036-03-02 F2 · derivative.exercise_date: The shares subject to the stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| March 03, 2026 Filed Mar 20, 2026 22:01 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 7,482 | $0.00 Strike: $22.50 | $0.00 |
DisclosureSEC source: 0001604689-26-000006 · form4-03202026_100313.xml · derivative · entry 1 Poole Jonathan · CIK 0001604689 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,482 Underlying: Common Stock · 7,482 shares Expires 2036-03-02 F1 · derivative.exercise_date: The shares subject to the stock option will vest in equal annual installments over three years following the date of grant such that the stock option will be fully vested on the third anniversary of the date of grant. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 16:14 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $7.06 | $0.00 |
DisclosureSEC source: 0001694665-20-000002 · wf-form4_158041886185768.xml · derivative · entry 2 Poole Jonathan · CIK 0001604689 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2030-01-27 F2 · derivative.exercise_date: These options will vest as to 50% of the total grant on January 9, 2022 and as to the remaining 50% on January 9, 2023. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 16:14 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 106,000 | $0.00 Strike: $7.06 | $0.00 |
DisclosureSEC source: 0001694665-20-000002 · wf-form4_158041886185768.xml · derivative · entry 1 Poole Jonathan · CIK 0001604689 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,000 Underlying: Common Stock · 106,000 shares Expires 2030-01-27 F1 · derivative.exercise_date: These options will vest in forty-eight (48) substantially equal installments at the end of each monthly anniversary of January 9, 2020, subject to continued employment on such dates. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 08:48 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001694665-19-000002 · wf-form4_154764650865511.xml · derivative · entry 1 Poole Jonathan · CIK 0001604689 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-01-14 F1 · derivative.exercise_date: These options will vest as to 25% of the total grant on the first anniversary of the grant date with the remainder vesting in equal quarterly installments over a three year period thereafter, subject to continued employment on such dates. Read SEC document |
| May 08, 2018 Filed May 10, 2018 18:06 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option · Derivative | 71,497 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-18-012422 · doc4.xml · derivative · entry 1 Poole Jonathan · CIK 0001604689 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,497 Underlying: Common Stock · 71,497 shares Expires 2028-05-08 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the grant date and vests in equal quarterly installments over a three year period thereafter. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 20:26 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 217,708 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001457612-18-000014 · wf-form4_151848517333702.xml · derivative · entry 1 Poole Jonathan · CIK 0001604689 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,708 Underlying: Common Stock · 217,708 shares Expires 2028-02-07 F1 · derivative.exercise_date: The options granted will vest annually in 48 equal monthly installments beginning on the first monthly anniversary of the grant date. The Company's Board of Directors also approved on February 8, 2018 that, subject to stockholder approval, Jonathan Poole will receive 257,292 additional options with the same grant date, at the same exercise price and pursuant to the same vesting schedule. Read SEC document |
| July 24, 2017 Filed Jul 24, 2017 17:30 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $3.09 | $0.00 |
DisclosureSEC source: 0001604689-17-000006 · wf-form4_150093180367725.xml · derivative · entry 3 Poole Jonathan · CIK 0001604689 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 45,000 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 10, 2017 by the reporting person. F3 · derivative.exercise_date: The option was granted on 2/2/2016 and vests in 48 equal monthly installments beginning on the first monthly anniversary of the grant date. Read SEC document |
| July 24, 2017 Filed Jul 24, 2017 17:30 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | SaleCommon Stock | 45,000 | $6.00 | $270,000.00 |
DisclosureSEC source: 0001604689-17-000006 · wf-form4_150093180367725.xml · nonDerivative · entry 2 Poole Jonathan · CIK 0001604689 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,247 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 10, 2017 by the reporting person. F2 · price: These shares were sold in multiple transactions at a price of $6.00. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold. Read SEC document |
| July 24, 2017 Filed Jul 24, 2017 17:30 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | Exercise / conversionCommon Stock | 45,000 | $3.09 | $139,050.00 |
DisclosureSEC source: 0001604689-17-000006 · wf-form4_150093180367725.xml · nonDerivative · entry 1 Poole Jonathan · CIK 0001604689 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 10, 2017 by the reporting person. Read SEC document |
| May 10, 2017 Filed May 10, 2017 16:44 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | Tax withholdingCommon Stock | 3,500 | $6.13 | $21,455.00 |
DisclosureSEC source: 0001604689-17-000004 · wf-form4_149444904447921.xml · nonDerivative · entry 4 Poole Jonathan · CIK 0001604689 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,247 F4 · kind: Shares sold to cover taxes on RSUs that vested on May 3, 2017. Read SEC document |
| May 08, 2017 Filed May 10, 2017 16:44 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | SaleCommon Stock | 6,213 | $6.51 | $40,446.63 |
DisclosureSEC source: 0001604689-17-000004 · wf-form4_149444904447921.xml · nonDerivative · entry 3 Poole Jonathan · CIK 0001604689 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,747 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $6.50 to $6.54, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 03, 2017 Filed May 10, 2017 16:44 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantCommon Stock | 23,810 | $0.00 | $0.00 |
DisclosureSEC source: 0001604689-17-000004 · wf-form4_149444904447921.xml · nonDerivative · entry 2 Poole Jonathan · CIK 0001604689 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,960 F2 · shares: The RSUs were granted in accordance with the Plan and will vest in full 18 months from the grant date, subject to Mr. Poole's continued employment with the Company. Read SEC document |
| May 03, 2017 Filed May 10, 2017 16:44 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantCommon Stock | 7,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001604689-17-000004 · wf-form4_149444904447921.xml · nonDerivative · entry 1 Poole Jonathan · CIK 0001604689 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,150 F1 · shares: The restricted stock units ("RSUs") were granted in accordance with Genocea Biosciences, Inc.'s (the "Company") 2014 Equity Incentive Plan (the "Plan") and vested immediately upon grant. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 16:17 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $4.67 | $0.00 |
DisclosureSEC source: 0001604689-17-000002 · wf-form4_148840302314907.xml · derivative · entry 1 Poole Jonathan · CIK 0001604689 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2027-02-28 F1 · derivative.exercise_date: 1. The option will vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date. Read SEC document |
| November 07, 2016 Filed Nov 9, 2016 17:32 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | PurchaseCommon Stock | 7,000 | $3.34 | $23,380.00 |
DisclosureSEC source: 0001604689-16-000007 · wf-form4_147873070879127.xml · nonDerivative · entry 1 Poole Jonathan · CIK 0001604689 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,213 F1 · balance_after: Amount adjusted to reflect shares acquired under the registrant's Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.